Skip to main content
Equibles

GELS · Gelteq Ltd

Track GELS — free

Use GELS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GELS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.38 +0.00 (+0.00%)
Rebalance outlook locked
Market Cap
$4.08M
Shares
10.71M
Volume · Nov 12 24.91K Avg daily vol (3M) 2.81M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.38 Open$0.41 Day$0.38–0.41 52W close$0.38–1.53 Avg vol 30d68K Short int228K · 2.1% of shares · 2.1d Short vol55% DataOct 2024–Nov 2026

Latest documents

2026
Nov 2
Late filing notice NT 20-F
Late filing notice

Gelteq Limited needs additional time to finalize financial statements for the fiscal year ended June 30, 2026, delaying its annual report. It expects to file within the fifteen-day grace period.

All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$3.41M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
-3,317.7%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-64.1%
Trailing year
Short interest
2.1%
Latest settlement · 2.1 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 18.7 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −40%
below
Price vs 50-day avg −29%
below
RSI (14) 31
neutral
MACD trend Negative
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −12%
trailing
6-month return −10%
trailing
YTD return −52%
this year
Relative strength −11%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
5 of 6 funds reported for Sep 30 · net +10.5K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.13% of shares out · ▼ -27.5% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 1-yr range
Squeeze score 46
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 229%
annualized · 1-yr
Max drawdown −75%
past year
ATR 11.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
4 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−40% Bearish
Price vs 50-day avg
−29% Bearish
RSI (14)
31 Neutral
MACD trend
Negative Bearish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Accumulating
5 of 6 funds reported for Sep 30 · net +10.5K sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
2.13% of shares out · ▼ -27.5% MoM · 2.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
6 holders — mid 1-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $2
vs 200-day avg -40% vs 50-day avg -29%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
GELS
Gelteq Ltd
this stock
$4.08M -52.4% — — 2.1%
TAK
Takeda Pharmaceutical Co Ltd
 $67.48B +35.5% — — 0.1%
GALDY
Galderma Group AG
 $54.01B +11.7% — — 0.0%
TEVA
Teva Pharmaceutical Industries Ltd
 $50.93B +39.9% +4.3% 99.2 2.4%
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
 $40.66B — — — 0.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
8
% held
1.1%
Reported
5 of 6
Top holder
TWO SIGMA SECURITIES, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
228.2K
Days to cover
2.1d
Change
-86.5K sh
View
Short Volume
Short vol %
55%
As of
Nov 12, 2026
Short Total
View
Fails to Deliver
FTD shares
6.4K
Value
$3.1K
As of
Oct 14, 2026
View
Off-Exchange
Off-exchange %
63.1%
Week of
Oct 5, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
NT 20-F
Filed
Nov 2, 2026
This year
6

Gelteq Limited needs additional time to finalize financial statements for the fiscal year ended June 30, 2026, delaying its annual report. It expects to file within the fifteen-day grace period.

View

Performance

5D 20D 120D MTD YTD
GELS -16.4% -11.6% -9.8% -22.3% -52.4%
SPY +3.3% -1.9% +1.5% +0.2% +11.0%
vs SPY -19.7% -9.7% -11.3% -22.5% -63.4%
Key facts CIK 1920092 CUSIP Q3978B109 13F (30d) 5 filings 5 filers Visit website Investor relations